Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Capital Expenditures (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Capital Expenditures for 7 consecutive years, with $262000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 92.95% to $262000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $374000.0, a 90.28% decrease, with the full-year FY2025 number at $374000.0, down 90.28% from a year prior.
  • Capital Expenditures was $262000.0 for Q4 2025 at Pliant Therapeutics, up from -$20000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $3.7 million in Q4 2024 to a low of -$2.6 million in Q3 2024.
  • A 5-year average of $225210.5 and a median of $242000.0 in 2021 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 917.65% in 2024; the steepest drop was 407.18% in 2024.
  • Pliant Therapeutics' Capital Expenditures stood at -$1.3 million in 2021, then dropped by 22.24% to -$1.6 million in 2022, then surged by 46.05% to -$860000.0 in 2023, then soared by 532.09% to $3.7 million in 2024, then plummeted by 92.95% to $262000.0 in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Capital Expenditures are $262000.0 (Q4 2025), -$20000.0 (Q2 2025), and $132000.0 (Q1 2025).